• SPX
  • $5,777.85
  • 1.14 %
  • $65.16
  • DJI
  • $42,221.88
  • 1.02 %
  • $427.28
  • N225
  • $38,474.90
  • 1.11 %
  • $421.23
  • FTSE
  • $8,172.39
  • -0.14 %
  • -$11.85
  • IXIC
  • $18,426.68
  • 1.36 %
  • $246.69
Lyell Immunopharma, Inc. (LYEL) Stock Price, News & Analysis

Lyell Immunopharma, Inc. (LYEL) Stock Price, News & Analysis

Currency in USD Disclaimer

$1.24

-$0.04

(-2.75%)

Day's range
$1.14
Day's range
$1.34
50-day range
$0.85
Day's range
$1.6
  • Country: US
  • ISIN: US55083R1041
52 wk range
$0.85
Day's range
$3.26
  • CEO: Dr. Lynn Seely M.D., Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -0.44
  • Piotroski Score 2.00
  • Grade Neutral
  • Symbol (LYEL)
  • Company Lyell Immunopharma, Inc.
  • Price $1.24
  • Changes Percentage (-2.75%)
  • Change -$0.04
  • Day Low $1.14
  • Day High $1.34
  • Year High $3.26

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/05/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $7.00
  • High Stock Price Target $12.00
  • Low Stock Price Target $1.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.90
  • Trailing P/E Ratio -2.7
  • Forward P/E Ratio -2.7
  • P/E Growth -2.7
  • Net Income $-234,632,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.